Edition:
United States

Cellectis SA (ALCLS.PA)

ALCLS.PA on Paris Stock Exchange

19.08EUR
16 Nov 2018
Change (% chg)

€-1.22 (-6.01%)
Prev Close
€20.30
Open
€19.99
Day's High
€20.08
Day's Low
€19.08
Volume
131,811
Avg. Vol
52,241
52-wk High
€29.78
52-wk Low
€19.08

Chart for

About

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid... (more)

Overall

Beta: 1.49
Market Cap(Mil.): €953.89
Shares Outstanding(Mil.): 42.11
Dividend: --
Yield (%): --

Financials

  ALCLS.PA Industry Sector
P/E (TTM): -- 79.36 29.34
EPS (TTM): -2.05 -- --
ROI: -26.15 -0.30 13.58
ROE: -23.95 -2.98 15.11

BRIEF-Cellectis Reports End-Sept Cash Of 475.9 Million Dollars

* REPORTED ON TUESDAY TOTAL CASH, CASH EQUIVALENTS AND CURRENT FINANCIAL ASSETS $475.9 MILLION AS OF SEPTEMBER 30, 2018

Nov 14 2018

BRIEF-Cellectis Operating Loss Widens To 21.7 Million US Dollars

* SAID ON WEDNESDAY ITS Q2 REVENUES WERE $5.0 MLN VS $6.5 MLN YEAR AGO

Aug 02 2018

BRIEF-Cellectis Publishes Methods to Improve Clinical Use of Chimeric Antigen Receptor T-Cell Therapy

* ANNOUNCED ON TUESDAY NOVEL METHODS TO IMPROVE THE CLINICAL USE OF CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY

Jun 13 2018

BRIEF-Cellectis Announces Approval Of Amendment To Protocol For UCART123 Phase 1 Clinical Trial

* ANNOUNCED ON TUESDAY APPROVAL OF AMENDMENT TO PROTOCOL FOR PHASE 1 CLINICAL TRIAL OF UCART123 PRODUCT CANDIDATE IN ACUTE MYELOID LEUKEMIA (AML) PATIENTS

May 23 2018

Earnings vs. Estimates